Lars Slørdal

3.5k total citations
138 papers, 2.6k citations indexed

About

Lars Slørdal is a scholar working on Public Health, Environmental and Occupational Health, Pediatrics, Perinatology and Child Health and Toxicology. According to data from OpenAlex, Lars Slørdal has authored 138 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Public Health, Environmental and Occupational Health, 25 papers in Pediatrics, Perinatology and Child Health and 23 papers in Toxicology. Recurrent topics in Lars Slørdal's work include Acute Lymphoblastic Leukemia research (19 papers), Forensic Toxicology and Drug Analysis (17 papers) and Pharmaceutical studies and practices (17 papers). Lars Slørdal is often cited by papers focused on Acute Lymphoblastic Leukemia research (19 papers), Forensic Toxicology and Drug Analysis (17 papers) and Pharmaceutical studies and practices (17 papers). Lars Slørdal collaborates with scholars based in Norway, United States and Singapore. Lars Slørdal's co-authors include A. Klovning, Jan Magnus Bjordal, Anne Elisabeth Ljunggren, Anders Andersen, Jørg Mørland, Olav Spigset, David J. Warren, Jarle Aarbakke, Jørgen G. Bramness and David J. Warren and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and Analytical Biochemistry.

In The Last Decade

Lars Slørdal

129 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lars Slørdal Norway 26 650 496 393 377 291 138 2.6k
Robert Taylor United States 29 515 0.8× 406 0.8× 75 0.2× 119 0.3× 143 0.5× 139 2.7k
Shereif H. Rezkalla United States 31 500 0.8× 198 0.4× 573 1.5× 48 0.1× 403 1.4× 69 3.9k
Jean‐Luc Cracowski France 41 312 0.5× 187 0.4× 128 0.3× 218 0.6× 662 2.3× 206 5.9k
David H. Lawson United Kingdom 28 855 1.3× 133 0.3× 62 0.2× 135 0.4× 400 1.4× 74 3.8k
Irene Riezzo Italy 33 278 0.4× 151 0.3× 218 0.6× 32 0.1× 744 2.6× 96 3.1k
Giorgio Basile Italy 24 145 0.2× 104 0.2× 74 0.2× 88 0.2× 396 1.4× 103 2.4k
Hallvard Gjerde Norway 32 710 1.1× 373 0.8× 1.5k 3.8× 43 0.1× 223 0.8× 129 3.5k
Toshiaki Sendo Japan 27 193 0.3× 185 0.4× 30 0.1× 69 0.2× 602 2.1× 210 2.7k
Else Marie Bartels Denmark 40 1.8k 2.8× 716 1.4× 40 0.1× 1.7k 4.6× 479 1.6× 151 6.6k
Giuseppe Mercuro Italy 42 228 0.4× 395 0.8× 19 0.0× 113 0.3× 990 3.4× 254 6.2k

Countries citing papers authored by Lars Slørdal

Since Specialization
Citations

This map shows the geographic impact of Lars Slørdal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Slørdal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Slørdal more than expected).

Fields of papers citing papers by Lars Slørdal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Slørdal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Slørdal. The network helps show where Lars Slørdal may publish in the future.

Co-authorship network of co-authors of Lars Slørdal

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Slørdal. A scholar is included among the top collaborators of Lars Slørdal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Slørdal. Lars Slørdal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Frost, Joachim, et al.. (2023). Findings of the neuromuscular blocking agent rocuronium in blood from deceased subjects several months after exposure: A report of two cases. Forensic Science International. 347. 111680–111680. 1 indexed citations
2.
Bramness, Jørgen G., et al.. (2017). The antipsychotic agent quetiapine is increasingly not used as such: dispensed prescriptions in Norway 2004–2015. European Journal of Clinical Pharmacology. 73(9). 1173–1179. 41 indexed citations
3.
Andersen, Anders, et al.. (2011). High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. British Journal of Clinical Pharmacology. 73(1). 106–114. 106 indexed citations
4.
Slørdal, Lars, et al.. (2009). Feilmedisinering hos pasienter innlagt i sykehus. Tidsskrift for Den norske legeforening. 129(13). 1337–1341. 3 indexed citations
5.
Bramness, Jørgen G., et al.. (2008). The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study. British Journal of Clinical Pharmacology. 67(2). 228–233. 32 indexed citations
6.
Spigset, Olav, et al.. (2008). Benzodiazepinliknende hypnotika – holdninger og forskrivningspraksis blant allmennleger. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
7.
Bjordal, Jan Magnus, et al.. (2007). Glukosamin – den store sukkerpillebløffen. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
8.
Reikvam, Åsmund, Sofie Hexeberg, Tore K Kvien, et al.. (2006). [Clinical use of COX inhibitors--a consensus].. PubMed. 126(5). 591–5. 5 indexed citations
9.
Nelson, Siri, Lars Slørdal, & Olav Spigset. (2006). [Generic drugs instead of brand drugs prescriptions--long overdue].. PubMed. 126(4). 441–3. 9 indexed citations
10.
Reikvam, Åsmund, Sofie Hexeberg, Tore K Kvien, et al.. (2006). Klinisk bruk av COX-hemmere – en konsensus. Tidsskrift for Den Norske Laegeforening. 2 indexed citations
11.
Nelson, Siri, Lars Slørdal, & Olav Spigset. (2006). Forskrivning av virkestoff i stedet for preparat – på høy tid. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
12.
Slørdal, Lars & Olav Spigset. (2005). Grunnleggende farmakokinetikk – distribusjon. Tidsskrift for Den Norske Laegeforening. 2 indexed citations
13.
Slørdal, Lars & Olav Spigset. (2005). Grunnleggende farmakokinetikk – absorpsjon. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
14.
Eldholm, Rannveig Sakshaug, et al.. (2003). [What information is given on adverse drug reactions from new drugs?].. PubMed. 123(17). 2414–7. 1 indexed citations
15.
Eldholm, Rannveig Sakshaug, et al.. (2003). Hvilken informasjon gis om bivirkninger av nye legemidler. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
16.
Spigset, Olav, et al.. (2003). Selektive COX-2-hemmere – holdninger og forskrivningspraksis blant allmennpraktikere. Tidsskrift for Den Norske Laegeforening. 1 indexed citations
17.
Aasebø, Ulf, et al.. (1997). Intrapleurally Instilled Mitoxantrone in Metastatic Pleural Effusions: A Phase II Study. Journal of Chemotherapy. 9(2). 106–111. 13 indexed citations
18.
19.
Slørdal, Lars, et al.. (1989). Radioprotection by murine and human tumor‐necrosis factor: Dose‐dependent effects on hematopoiesis in the mouse. European Journal Of Haematology. 43(5). 428–434. 29 indexed citations
20.
Gutteberg, Tore Jarl, Lars Slørdal, & Svein Kolmannskog. (1987). Lactoferrin and C-Reactive Protein in Response to Cytostatic Drugs with Emphasis on Methotrexate. Pediatric Hematology and Oncology. 4(4). 315–322. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026